Chronic obstructive pulmonary disease hospital admissions and drugs - Unexpected positive associations: A retrospective general practice cohort study

npj Primary Care Respiratory Medicine

Volumn 24, Issue , 2014, Pages

  Harries, Timothy H ^a   Seed, Paul T ^a   Jones, Simon ^b   Schofield, Peter ^a   White, Patrick ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; SALMETEROL; TIOTROPIUM BROMIDE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CORTICOSTEROID THERAPY; DRUG COST; FEMALE; GENERAL PRACTICE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACIST; PREDICTION; PREDICTOR VARIABLE; PRESCRIPTION; PREVALENCE; PRIMARY MEDICAL CARE; PUBLICATION; RETROSPECTIVE STUDY; UNITED KINGDOM; CLINICAL PRACTICE; EPIDEMIOLOGY; HOSPITALIZATION; PROCEDURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; STATISTICS AND NUMERICAL DATA;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; BRONCHODILATOR AGENTS; GENERAL PRACTICE; GREAT BRITAIN; HOSPITALIZATION; HUMANS; MUSCARINIC ANTAGONISTS; PHYSICIAN'S PRACTICE PATTERNS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES;

EID: 84904498205     PISSN: None     EISSN: 20551010     Source Type: Journal    
DOI: 10.1038/npjpcrm.2014.6     Document Type: Article

References (30)

1. The Burden of Lung Disease. 2nd Edn. A Statistics report from the BTS. http://www.brit-thoracic.org.uk/Portals/0/Library/BTS%20Publications/ burdeon-of-lung-disease2007.pdf, 2006.
2. NICE. CG101 Chronic obstructive pulmonary disease (update): NICE guideline. at http://publications.nice.org.uk/chronic-obstructive-pulmonary- disease-cg101.
3. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449-456. (Pubitemid 36173708)
4. Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789. (Pubitemid 46294610)
5. Wedzicha JA, Calverley PMA, Seemungal TA, Hagan G, Ansari Z, Stockley R. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008; 177: 19-26.
6. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554.
7. Prescription Cost Analysis England 2012. http://www.hscic.gov.uk/ searchcatalogue?productid=11412&q= title%3a%22Prescription+Cost+Analysis%2c+England%22+!quarterly&sort= Relevance&size=10&page=1#top, 2013.
8. Spencer S, Karner C, Cates CJ, Evans DJ. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011; 12: CD007033.
9. Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 9: CD006829.
10. Van den Bruel A, Gailly J, Neyt M. Does tiotropium lower exacerbation and hospitalization frequency in COPD patients: results of a meta-analysis. BMC Pulm Med 2010; 10: 50.
11. Yohannes AM, Willgoss TG, Vestbo J. Tiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomes. Respir Care 2011; 56: 477-487.
12. Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 7: CD009285.
13. Lee TA, Wilke C, Joo M, Stroupe KT, Krishnan JA, Schumock GT et al. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease. Arch Intern Med 2009; 169: 1403-1410.
14. Neyt M, Devriese S, Thiry N, Van den Bruel A. Tiotropium's cost-effectiveness for the treatment of COPD: a cost-utility analysis under real-world conditions. BMC Pulm Med 2010; 10: 47.
15. NHS Information Centre. Hospital Prescribing, England: 2011. https://catalogue.ic.nhs.uk/publications/prescribing/primary/hosp-pres-eng-2011/ hosp-pres-eng-2011-rep.pdf, 2012.
16. Sin DD, Man SFP. Steroids in COPD: still up in the air? Eur Respir J 2010; 35: 949-951.
17. Bourbeau J. Preventing hospitalization for COPD exacerbations. Semin Respir Crit Care Med 2010; 31: 313-320.
18. Roland M. Linking physicians' pay to the quality of care - a major experiment in the United Kingdom. N Engl J Med 2004; 351: 1448-1454. (Pubitemid 39288172)
19. Independent Review of the impact of the Freedom of Information Act. A report prepared for the department for constitutional affairs. http://webarchive.nationalarchives.gov.uk/%2B/http:/www.dca.gov.uk/foi/ reference/foi-independent-review.pdf, 2006.
20. Payne RA, Abel GA. UK indices of multiple deprivation - a way to make comparisons across constituent countries easier. Health Stat Q 2012; 53: 22-37.
21. Data Protection Act 1998. http://www.legislation.gov.uk/ukpga/1998/29/ contents.
22. Kim HJ. Spurious correlation between ratios with a common divisor. Stat Prob Lett 1999; 44: 383-386.
23. Kronmal RA. Spurious correlation and the fallacy of the ratio standard revisited. J R Stat Soc 1993; 156: 379-392.
24. Nacul L, Soljak M, Samarasundera E, Hopkinson NS, Lacerda E, Indulkar T et al. COPD in England: a comparison of expected, model-based prevalence and observed prevalence from general practice data. J Public Health (Oxf) 2011; 33: 108-116.
25. Welsh EJ, Cates CJ, Poole P. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2010; 5: CD007891.
26. Improving data quality in the NHS: 2010 - Audit Commission. http://www.audit-commission.gov.uk/2010/08/improving-data-quality-in-the-nhs- 2010/.
27. Beeh K-M, Hederer B, Glaab T, Müller A, Rutten-van Moelken M, Kesten S et al. Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations. Int J Chron Obstruct Pulmon Dis 2009; 4: 119-125.
28. Barr RG, Bourbeau J, Camargo CA, Ram FSF. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 2006; 61: 854-862. (Pubitemid 44570305)
29. Mauskopf JA, Baker CL, Monz BU, Juniper MD. Cost effectiveness of tiotropium for chronic obstructive pulmonary disease: a systematic review of the evidence. J Med Econ 2010; 13: 403-417.
30. Suissa S. Number needed to treat in COPD: exacerbations versus pneumonias. Thorax 2013; 68: 540-543.